Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Stardust Power NASDAQ:SDST$0.65 -0.06 (-8.82%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Stardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.Market Capitalization$37.00 millionConsensus RatingBuyConsensus Price Target$5.11 (+684.1% Upside)Volume97,432 sharesAverage Volume393,748 sharesToday's Range$0.64▼$0.67 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. OS Therapies NYSE:OSTX$1.78 -0.02 (-1.11%) As of 09:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. More about OS TherapiesMarket Capitalization$38.67 millionConsensus RatingBuyConsensus Price Target$18.00 (+911.2% Upside)Volume6,225 sharesAverage Volume479,748 sharesToday's Range$1.80▼$1.813. Denison Mines NYSEAMERICAN:DNN$1.48 -0.03 (-1.66%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison MinesMarket Capitalization$1.33 billionP/E Ratio-148.50Consensus RatingBuyConsensus Price Target$3.00 (+102.0% Upside)Volume133,141 sharesAverage Volume31.78 million shares4. OnKure Therapeutics NASDAQ:OKUR$1.83 +0.00 (+0.05%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. More about OnKure TherapeuticsMarket Capitalization$24.82 millionP/E Ratio-0.15Consensus RatingBuyConsensus Price Target$32.33 (+1,638.4% Upside)Volume4,384 sharesAverage Volume86,489 shares5. GeoVax Labs NASDAQ:GOVX$0.94 +0.03 (+3.28%) As of 09:04 AM EasternGeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. More about GeoVax LabsMarket Capitalization$14.36 millionP/E Ratio-0.26Consensus RatingBuyConsensus Price Target$11.10 (+1,074.6% Upside)Volume4,538 sharesAverage Volume544,055 shares6. Reviva Pharmaceuticals NASDAQ:RVPH$0.79 0.00 (-0.13%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$37.25 millionP/E Ratio-0.72Consensus RatingBuyConsensus Price Target$10.00 (+1,154.7% Upside)Volume7,199 sharesAverage Volume1.13 million shares7. Quince Therapeutics NASDAQ:QNCX$0.82 -0.02 (-1.95%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$36.18 millionP/E Ratio-0.66Consensus RatingBuyConsensus Price Target$8.00 (+869.7% Upside)Volume3,368 sharesAverage Volume282,816 shares8. Cardiol Therapeutics NASDAQ:CRDL$1.09 -0.02 (-1.71%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol TherapeuticsMarket Capitalization$90.87 millionP/E Ratio-2.82Consensus RatingBuyConsensus Price Target$8.40 (+663.6% Upside)Volume1,444 sharesAverage Volume368,226 shares9. Immunic NASDAQ:IMUX$0.97 0.00 (-0.33%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about ImmunicMarket Capitalization$93.04 millionP/E Ratio-0.79Consensus RatingBuyConsensus Price Target$13.20 (+1,255.2% Upside)Volume24,137 sharesAverage Volume712,583 shares10. Ur-Energy NYSEAMERICAN:URG$0.70 -0.04 (-5.02%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur-EnergyMarket Capitalization$258.88 millionP/E Ratio-5.47Consensus RatingBuyConsensus Price Target$2.30 (+226.7% Upside)Volume28,097 sharesAverage Volume4.15 million shares11. Western Copper & Gold NYSE:WRN$1.07 -0.07 (-6.14%) As of 05/14/2025 04:00 PM EasternWestern Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & GoldMarket Capitalization$214 millionP/E Ratio-53.50Consensus RatingBuyConsensus Price Target$4.25 (+297.2% Upside)Volume1.42 million sharesAverage Volume334,446 shares12. HIVE Digital Technologies NASDAQ:HIVE$1.82 -0.09 (-4.61%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.HIVE Digital Technologies Ltd. operates as a cryptocurrency mining company in Canada, Sweden, and Iceland. The company engages in the mining and sale of digital currencies, including Ethereum Classic, Bitcoin, and other coins. More about HIVE Digital TechnologiesMarket Capitalization$312.71 millionP/E Ratio-36.70Consensus RatingBuyConsensus Price Target$7.64 (+319.2% Upside)Volume159,453 sharesAverage Volume6.56 million shares13. Lucid Diagnostics NASDAQ:LUCD$1.25 -0.03 (-2.34%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$134.36 millionP/E Ratio-1.12Consensus RatingBuyConsensus Price Target$3.50 (+180.0% Upside)Volume19,738 sharesAverage Volume493,371 shares14. Rani Therapeutics NASDAQ:RANI$0.52 -0.04 (-6.97%) As of 09:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More about Rani TherapeuticsMarket Capitalization$30.64 millionP/E Ratio-0.50Consensus RatingBuyConsensus Price Target$12.00 (+2,216.6% Upside)Volume23,610 sharesAverage Volume779,941 shares15. FibroBiologics NASDAQ:FBLG$0.82 -0.01 (-1.38%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologicsMarket Capitalization$31.61 millionP/E Ratio-2.43Consensus RatingBuyConsensus Price Target$13.00 (+1,485.4% Upside)Volume1,667 sharesAverage Volume294,112 shares16. Gain Therapeutics NASDAQ:GANX$1.80 -0.06 (-2.96%) As of 09:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. More about Gain TherapeuticsMarket Capitalization$53.68 millionP/E Ratio-1.66Consensus RatingBuyConsensus Price Target$8.20 (+354.3% Upside)Volume3,265 sharesAverage Volume305,233 shares17. Prime Medicine NYSE:PRME$1.20 -0.02 (-1.24%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. More about Prime MedicineMarket Capitalization$156.74 millionP/E Ratio-0.58Consensus RatingBuyConsensus Price Target$12.83 (+973.9% Upside)Volume29,116 sharesAverage Volume1.23 million shares18. Context Therapeutics NASDAQ:CNTX$0.78 -0.01 (-1.27%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$69.97 millionP/E Ratio-0.86Consensus RatingBuyConsensus Price Target$5.40 (+592.3% Upside)Volume504 sharesAverage Volume290,895 shares19. Acrivon Therapeutics NASDAQ:ACRV$1.12 -0.03 (-2.19%) As of 09:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. More about Acrivon TherapeuticsMarket Capitalization$34.65 millionP/E Ratio-0.41Consensus RatingBuyConsensus Price Target$19.17 (+1,619.0% Upside)Volume7,053 sharesAverage Volume202,313 shares20. Zura Bio NASDAQ:ZURA$1.18 +0.01 (+0.43%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. More about Zura BioMarket Capitalization$80.68 millionP/E Ratio-1.69Consensus RatingBuyConsensus Price Target$14.33 (+1,114.7% Upside)Volume1,010 sharesAverage Volume391,779 shares21. Nkarta NASDAQ:NKTX$1.74 -0.14 (-7.22%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More about NkartaMarket Capitalization$123.11 millionP/E Ratio-0.92Consensus RatingBuyConsensus Price Target$14.67 (+745.3% Upside)Volume180,833 sharesAverage Volume1.25 million shares22. ProQR Therapeutics NASDAQ:PRQR$1.53 -0.02 (-1.29%) As of 09:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More about ProQR TherapeuticsMarket Capitalization$160.98 millionP/E Ratio-4.78Consensus RatingBuyConsensus Price Target$8.00 (+422.9% Upside)Volume8,423 sharesAverage Volume620,015 shares23. Aclaris Therapeutics NASDAQ:ACRS$1.18 +0.01 (+0.42%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris TherapeuticsMarket Capitalization$128.31 millionP/E Ratio-2.28Consensus RatingBuyConsensus Price Target$10.00 (+743.9% Upside)Volume41,385 sharesAverage Volume861,513 shares24. Compass Therapeutics NASDAQ:CMPX$1.96 -0.04 (-1.75%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. More about Compass TherapeuticsMarket Capitalization$273.66 millionP/E Ratio-5.35Consensus RatingBuyConsensus Price Target$13.13 (+567.9% Upside)Volume3,266 sharesAverage Volume907,348 shares25. Larimar Therapeutics NASDAQ:LRMR$1.74 -0.05 (-3.07%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. More about Larimar TherapeuticsMarket Capitalization$112.05 millionP/E Ratio-1.52Consensus RatingBuyConsensus Price Target$19.63 (+1,030.5% Upside)Volume6,429 sharesAverage Volume763,613 shares More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
